Shares of Esperion Therapeutics Inc. (ESPR) are up 31.04% to $32.00 in pre-market trading Thursday after the company announced positive top-line results from ETC-1002-008, a Phase 2b study evaluating the efficacy and safety of ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance. Following the news, Esperion had its price target raised to $38 from $26 by analysts at Credit Suisse (CS). The firm’s price target would suggest a potential upside of 55.61% from the stock’s previous close.
On valuation-measures, shares of Esperion Therapeutics, currently valued at $376.83M, have a median Wall Street price target of $31.50 with a high target of $35.00. Approximately 148,634 shares changed hands during Wednesday’s trading session, compared to the stock’s average daily volume of 41,277.
In the past 52 weeks, shares of the clinical stage biopharmaceutical company have traded between a low of $10.90 and a high of $24.94 with the 50-day MA and 200-day MA located at $16.80 and $15.23 levels, respectively. Additionally, shares of ESPR trade at a P/B ratio of 6.41 and have a Relative Strength Index (RSI) and MACD indicator of 82.09 and +5.27, respectively.
ESPR currently prints a one year return of about 29.41% and a year-to-date return of around 77.73%.
Shares of Tesla Motors, Inc. (TSLA) are up more than 3% in pre-market trading following a cryptic tweet sent out by Tesla CEO Elon Musk Wednesday night saying it is “about time to unveil the D and something else”. The tweet included an accompanying image which mentioned a date, Oct. 9.
It is unclear what the “D”, “Oct. 9”, or “something else” entails, but according to several reports, the wording, the image, and the date could suggest a new model the electric carmaker might unveil on that day.
On valuation-measures, shares of Tesla Motors have a forward P/E of 71.93. P/E to growth ratio is 4.57, while t-12 profit margin is (6.83%). EPS registers at ($1.35). The company has a market cap of $29.94B and a median Wall Street price target of $300.00 with a high target of $400.00.
On trading-measure, TSLA has a beta of 1.36 and a short float of 24.42%. In the past 52 weeks, shares of Palo Alto, California-based electric carmaker have traded between a low of $116.10 and a high of $291.42 with the 50-day MA and 200-day MA located at $262.55 and $228.18 levels, respectively.
TSLA currently prints a one year return of about 24.48% and a year-to-date return of around 59.70%.
Ticker traded recently up $7.26 to $247.50.
Autodesk, Inc. (ADSK) had its rating hiked to ‘Outperform’ from ‘Neutral’ by analysts at Credit Suisse (CS) on Thursday, who said the company’s business model changes should drive meaningful long-term upside to revenue. The analysts raised the price target to $70 from $50 implying 22.46% expected return from ticker’s current PPS. Autodesk was also upgraded this morning to ‘Neutral’ from ‘Sell’ and had its price target raised to $59 from $37 at Citigroup (C).
Autodesk shares recently rose $1.50, 2.70% to $57.10, the second highest level in the last 5 years. The stock is up more than 10.61% this year and has risen more than 33% over the past 12 months.
Ariad Pharmaceuticals Inc. (ARIA) is up 0.45 to $5.73 in pre-market trading on news that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the FDA for the treatment of patients with anaplastic lymphoma kinase positive metastatic non-small cell lung cancer who are resistant to crizotinib. This designation is based on results from the ongoing Phase 1/2 trial that show sustained anti-tumor activity of AP26113 in patients with ALK+ NSCLC, including patients with active brain metastases.
Ariad Pharma currently valued at $987.42M, has a median Wall Street price target of $8.00 with a high target of $14.00.
In the past 52 weeks, shares of the Cambridge, Massachusetts-based company have traded between a low of $2.15 and a high of $19.18 with the 50-day MA and 200-day MA located at $5.88 and $6.47 levels, respectively. Additionally, shares of ARIA trade at a P/E ratio of (0.11) and have a Relative Strength Index (RSI) and MACD indicator of 36.67 and (0.19), respectively.
ARIA currently prints a one year loss of about 72.05% and a year-to-date loss of around 22.58%.